These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7868157)

  • 1. Endothelial cell activation and thromboregulation during xenograft rejection.
    Bach FH; Robson SC; Ferran C; Winkler H; Millan MT; Stuhlmeier KM; Vanhove B; Blakely ML; van der Werf WJ; Hofer E; de Martin R; Hancock WW
    Immunol Rev; 1994 Oct; 141():5-30. PubMed ID: 7868157
    [No Abstract]   [Full Text] [Related]  

  • 2. A synthetic dextran derivative inhibits complement activation and complement-mediated cytotoxicity in an in vitro model of hyperacute xenograft rejection.
    Thomas H; Maillet F; Letourneur D; Jozefonvicz J; Kazatchkine MD; Fischer E
    Transplant Proc; 1996 Apr; 28(2):593-4. PubMed ID: 8623290
    [No Abstract]   [Full Text] [Related]  

  • 3. Activation of endothelial cells in hyperacute xenograft rejection.
    Geller RL; Bach FH; Vercellotti GM; Nistler RS; Bolman RM; Fischel RJ; Leventhal J; Platt JL
    Transplant Proc; 1992 Apr; 24(2):592. PubMed ID: 1566442
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms of tissue injury in hyperacute xenograft rejection.
    Platt JL
    ASAIO J; 1992; 38(1):8-16. PubMed ID: 1554921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hyperacute xenograft rejection by intravenous immunoglobulin in the pig-to-human combination.
    Gautreau C; Cardoso J; Woimant G; Zhao Z; Chereau C; Cherruau B; Vandeginste N; Devillier P; Houssin D
    Transplant Proc; 1994 Jun; 26(3):1281. PubMed ID: 8029908
    [No Abstract]   [Full Text] [Related]  

  • 6. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection.
    Ghanekar A; Mendicino M; Liu H; He W; Liu M; Zhong R; Phillips MJ; Levy GA; Grant DR
    J Immunol; 2004 May; 172(9):5693-701. PubMed ID: 15100314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attempts to prepare suitable complement regulatory molecules for clinical xenotransplantation.
    Miyagawa S; Matsunami K; Yoshitatsu M; Mikata S; Matsuda H; Shirakura R
    J Card Surg; 2001; 16(6):429-38. PubMed ID: 11925023
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombotic microangiopathy: the next big hurdle for xenotransplantation.
    O'Connell PJ
    J Am Soc Nephrol; 2005 Sep; 16(9):2529-30. PubMed ID: 16093447
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperacute xenograft rejection in the swine-to-human donor-recipient combination. In vitro analysis of complement activation.
    Zhao Z; Termignon JL; Cardoso J; Chéreau C; Gautreau C; Calmus Y; Houssin D; Weill B
    Transplantation; 1994 Jan; 57(2):245-9. PubMed ID: 8310516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential mechanism of abnormal thromboregulation in xenograft rejection: loss of ecto-ATPases upon endothelial cell activation.
    Robson SC; Candinas D; Siegel JB; Kopp C; Millan M; Hancock WW; Bach FH
    Transplant Proc; 1996 Apr; 28(2):536. PubMed ID: 8623252
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of cytokines in rejection of discordant xenotransplants.
    Saadi S; Takahashi T; Nagayasu T; Holzknecht RA; Platt JL
    Transplant Proc; 1999; 31(1-2):911-2. PubMed ID: 10083400
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic engineering as an approach to xenotransplantation.
    Bach FH
    World J Surg; 1997; 21(9):913-6. PubMed ID: 9361504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic engineering of endothelial cells to ameliorate xenograft rejection.
    Bach FH; Robson SC; Wrighton CJ; Stuhlmeier K; Ferran C; Winkler H
    Clin Transplant; 1996 Feb; 10(1 Pt 2):124-7. PubMed ID: 8680048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of IgM anti-endothelial antibodies results in prolonged cardiac xenograft survival.
    Fischel RJ; Bolman RM; Platt JL; Najarian JS; Bach FH; Matas AJ
    Transplant Proc; 1990 Jun; 22(3):1077-8. PubMed ID: 2190373
    [No Abstract]   [Full Text] [Related]  

  • 15. Alive and kicking: endothelium at the geographic nexus of vascular rejection.
    Mazer SP; Pinsky DJ
    Circ Res; 2002 Dec; 91(12):1085-8. PubMed ID: 12480807
    [No Abstract]   [Full Text] [Related]  

  • 16. The in vitro and in vivo effects of anti-galactose antibodies on endothelial cell activation and xenograft rejection.
    Xu H; Yin D; Naziruddin B; Chen L; Stark A; Wei Y; Lei Y; Shen J; Logan JS; Byrne GW; Chong AS
    J Immunol; 2003 Feb; 170(3):1531-9. PubMed ID: 12538718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cell-surface glycoproteins in the activation of endothelial cells by antibody and complement.
    Lindman BJ; Noreen HJ; Geller RL; Dalmasso AP; Bach FH; Platt JL
    Transplant Proc; 1992 Apr; 24(2):586-7. PubMed ID: 1566439
    [No Abstract]   [Full Text] [Related]  

  • 18. Are anti-endothelial cell antibodies a pre-requisite for the acute vascular rejection of xenografts?
    Dorling A
    Xenotransplantation; 2003 Jan; 10(1):16-23. PubMed ID: 12535222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complement system in xenotransplantation.
    Dalmasso AP
    Immunopharmacology; 1992; 24(2):149-60. PubMed ID: 1473965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor.
    Dalmasso AP; Platt JL
    Transplantation; 1993 Nov; 56(5):1171-6. PubMed ID: 8249120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.